News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Regeneus (RGS.AX) Receives R&D Tax Incentive Of $2.6 Million



8/29/2017 10:52:27 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Sydney, Aug 29, 2017 - (ABN Newswire) - Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today reported that it has received $2.6m from the Australian Government's Research and Development tax incentive program for activities conducted during the financial year 2017.

The Research and Development (R&D) tax incentive encourages companies to engage in R&D and innovation, benefiting Australia, by providing a tax offset for eligible R&D activities.

WEB: Regeneus receives R&D tax incentive refund of $2.6m

About: Regeneus Ltd

Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of innovative cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology.

Read at BioSpace.com


comments powered by Disqus
Regeneus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES